This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Amphetamine	The serum concentration of Amphetamine can be decreased when it is combined with Zinc ascorbate.
Benzphetamine	The serum concentration of Benzphetamine can be decreased when it is combined with Zinc ascorbate.
Bleomycin	The therapeutic efficacy of Bleomycin can be decreased when used in combination with Zinc ascorbate.
Bortezomib	The therapeutic efficacy of Bortezomib can be decreased when used in combination with Zinc ascorbate.
Cabotegravir	The serum concentration of Cabotegravir can be decreased when it is combined with Zinc ascorbate.

Food Interactions

Avoid milk and dairy products. Separate the use of zinc from these products by at least 2 hours before administration. Separate for 2 hours after administration if these products also contain phosphorus.
Do not take with bran and high fiber foods. For optimal efficacy, take zinc at least 2 hours before or after eating high-fiber foods.
Take on an empty stomach. Take at least 1 hour before and 2 hours after eating for optimal absorption. Zinc can be taken with food to reduce gastrointestinal upset.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Ascorbic acid	unknown	PQ6CK8PD0R	50-81-7	CIWBSHSKHKDKBQ-JLAZNSOCSA-N

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
C-1000 Plus Zinc & Potassium	Zinc ascorbate (5 mg) + Calcium ascorbate (1 g) + Potassium aspartate (12 mg) + Potassium citrate (13 mg)	Tablet	Oral	Nu Life Nutrition Ltd.	1987-12-31	2005-03-15
PramLyte	Zinc ascorbate (1 mg/1) + 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium (6.4 mg/1) + 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium (800 ug/1) + Betaine (500 ug/1) + Citric acid monohydrate (1.83 mg/1) + Cobamamide (50 ug/1) + Cocarboxylase (25 ug/1) + Escitalopram oxalate (10 mg/1) + Ferrous cysteine glycinate (13.6 mg/1) + Flavin adenine dinucleotide (25 ug/1) + Folic acid (1 mg/1) + Leucovorin (2.5 mg/1) + Levomefolate magnesium (7 mg/1) + Magnesium ascorbate (24 mg/1) + NADH (25 ug/1) + Phosphatidyl serine (12 mg/1) + Pyridoxal phosphate (25 ug/1) + Sodium citrate (3.67 mg/1)	Kit	Oral	Allegis Pharmaceuticals, LLC	2015-09-11	2016-01-04

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
EnBrace HR	Zinc ascorbate (1 mg/1) + 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium (6.4 mg/1) + 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium (800 ug/1) + Betaine (500 ug/1) + Cobamamide (50 ug/1) + Cocarboxylase (25 ug/1) + Ferrous cysteine glycinate (13.6 mg/1) + Flavin adenine dinucleotide (25 ug/1) + Folic acid (1 mg/1) + Magnesium L-threonate (1 mg/1) + Leucovorin (2.5 mg/1) + Levomefolate magnesium (5.23 mg/1) + Magnesium ascorbate (24 mg/1) + NADH (25 ug/1) + Phosphatidyl serine (12 mg/1) + Pyridoxal phosphate (25 ug/1)	Capsule, delayed release pellets	Oral	Jaymac Pharma	2011-08-12	Not applicable

Chemical Identifiers

UNII: 9TI35313XW
CAS number: 331242-75-2
InChI Key: WWRJFSIRMWUMAE-ZZMNMWMASA-L
InChI: InChI=1S/2C6H8O6.Zn/c2*7-1-2(8)5-3(9)4(10)6(11)12-5;/h2*2,5,7-10H,1H2;/q;;+2/p-2/t2*2-,5+;/m00./s1
IUPAC Name: zinc(2+) bis((2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate)
SMILES: [Zn++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO

References

General References

Not Available

External Links

ChemSpider: 34988958
Wikipedia: Mineral_ascorbates

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Withdrawn	Treatment	Menstrual Related Mood Disorder / Premenstrual Dysphoric Disorder (PMDD) / Premenstrual Syndrome (PMS) / Premenstrual tension with edema	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Tablet	Oral
Capsule, liquid filled	Oral
Capsule, delayed release pellets	Oral
Kit	Oral

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	43.4 mg/mL	ALOGPS
logP	-1.6	ALOGPS
logP	-1.9	Chemaxon
logS	-0.98	ALOGPS
pKa (Strongest Acidic)	4.36	Chemaxon
pKa (Strongest Basic)	-3	Chemaxon
Physiological Charge	-1	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	3	Chemaxon
Polar Surface Area	110.05 Å²	Chemaxon
Rotatable Bond Count	4	Chemaxon
Refractivity	47.58 m³·mol^-1	Chemaxon
Polarizability	14.58 Å³	Chemaxon
Number of Rings	2	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST): Not Available
Spectra: Not Available
Chromatographic Properties: Collision Cross Sections (CCS)
Not Available

Drug created at July 06, 2018 22:27 / Updated at June 12, 2020 16:53

Zinc ascorbate

Identification

Structure for Zinc ascorbate (DB14485)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)